Table 1.
Growth inhibition of Bufalin (BF) on human cancer cell lines after 24–72H treatment
| Cancer type | Cell line | 24H IC50 | 48H IC50 | 72H IC50 | Refs. |
|---|---|---|---|---|---|
| Breast | MCF-7 | 317.9 ± 1.5 nM | 46.5 ± 1.4 nM | Yan et al. [125] | |
| 3.2 nM | Wang et al. [56] | ||||
| MCF-7/ADR | 100.17 ± 30.16 nmol/L | Wang et al. [126] | |||
| MCF-10A | 465.2 ± 25.9 nM | Clifford et al. [31] | |||
| MCF10CA1 | 635.2 ± 171.8 nM | Clifford et al. [31] | |||
| MDA-MB-231 | 934.1 ± 2.0 nM | 513.3 ± 1.6 nM | Yan et al. [125] | ||
| 263.3 ± 68.24 nmol/L | Wang et al. [126] | ||||
| 936.4 ± 4.9 nM | Clifford et al. [31] | ||||
| 20.0 nM | Song et al. [55] | ||||
| MDA-MB-231-LM3-3 | 16.6 nM | Song et al. [55] | |||
| SUM149PT | 16.6 nM | Song et al. [55] | |||
| SUM159PT | 15.9 nM | Song et al. [55] | |||
| Cervical | Hela | 154 ± 21.5 nM | 37.5 ± 2.15 nM | 11.8 ± 2.13 nM | Pan et al. [127] |
| Colorectal | SW620 | 76.72 ± 6.21 nmol/L | 34.05 ± 4.21 nmol/L | 16.7 ± 6.37 nmol/L | Zhu et al. [128] |
| 287.35 ± 4.34 nM | 57.63 ± 7.80 nM | 20.39 ± 1.95 nM | Zhang et al. [129] | ||
| HCT116 | 82.6 μmol/L | Qiu et al. [130] | |||
| 0.243 μM | 0.024 μM | Wang et al. [131] | |||
| LoVo | 56.778 ± 7.34 nM | 11.48 ± 2.89 nM | 6.64 ± 2.79 nM | Zhang et al. [129] | |
| Endometrial | Ishikawa | 0.7 ng/mL | Takai et al. [132] | ||
| HHUA | 0.5 ng/mL | Takai et al. [132] | |||
| HEC-1B | 0.6 ng/mL | Takai et al. [132] | |||
| Esophageal | Eca-109 | 1.0 μM | Lv et al. [133] | ||
| EC9706 | 1.0 μM | Lv et al. [133] | |||
| TE5 | 2.6 μM | Lv et al. [133] | |||
| TE11 | 4.9 μM | Lv et al. [133] | |||
| Hec2 | 3.8 μM | Lv et al. [133] | |||
| Gallbladder | GBC-SD | 48.12 ± 2.03 nM | 28.23 ± 1.78 nM | Jiang et al. [45] | |
| SGC996 | 125.03 ± 5.16 nM | 102.78 ± 3.21 nM | Jiang et al. [45] | ||
| Gastric | SGC7901 | > 800 nmol/L | Li et al. [134] | ||
| MGC803 | 160 ± 0.87 nmol/L | Li et al. [134] | |||
| Liver | HepG2 | 182.30 ± 13.78 nM | Li et al. [27] | ||
| 307 ± 87 nM | Ozdemir et al. [84] | ||||
| 33.65 nmol/L | Gao et al. [60] | ||||
| 143.2 nM | Miao et al. [49] | ||||
| PLC/PRF/5 | 52.20 ± 14.16 nM | Li et al. [27] | |||
| 157.87 nmol/L | Gao et al. [60] | ||||
| SMMC7721 | 97.74 ± 8.83 nM | Li et al. [27] | |||
| SK-HEP-1 | 110.33 ± 5.32 nM | Tsai et al. [135] | |||
| Leukemia | NB4 | 40 nmol/L | 27 nmol/L | 17 nmol/L | Zhai et al. [136] |
| K562 | 0.0943 μmol/L | Zhai et al. [136] | |||
| K562/VCR | 0.0401 μmol/L | Zhai et al. [136] | |||
| HEL | 0.046 μmol/L | Wang et al. [137] | |||
| Lung | A549 | 4.5 nM | Wang et al. [56] | ||
| 56.14 ± 6.72 nmol/L | 15.57 ± 4.28 nmol/L | Zhu et al. [138] | |||
| 8.15 ± 0.69 nmol/L | Sun et al. [92] | ||||
| 22.00 ± 3.53 nM | 10.20 ± 1.01 nM | Liu et al. [36] | |||
| Melanoma | A375.S2 | 450.38 nM | Hsiao et al. [44] | ||
| Oral | CAL27 | 125 nM | Tsai et al. [139] | ||
| 122.6 nM | Tian et al. [140] | ||||
| Osteosarcoma | U-2OS | 0.297 μM | Zhang et al. [141] | ||
| 8.49 ± 2.1 μg/L | Yin et al. [142] | ||||
| U-2OS/MTX300 | 10.19 ± 1.7 μg/L | Yin et al. [142] | |||
| Saos-2 | 0.318 μΜ | Zhang et al. [141] | |||
| Ovarian | SK-OV-3 | 1.0 ng/mL | Takai et al. [132] | ||
| OMC-3 | 0.6 ng/mL | Takai et al. [132] | |||
| Tongue | SCC-4 | 300 nM | Chou et al. [143] | ||
| Pancreatic | Capan-2 | 159.2 nM | Tian et al. [140] | ||
| Non-cancerous | Breast epithelial cell 184D | 384.6 ± 36.5 nM | Clifford et al. [31] | ||
| Breast epithelial cell 184A | 295.9 ± 10.5 nM | Clifford et al. [31] | |||
| Mouse normal hepatocyte | No cytotoxicity at 10 μM | Song et al. [55] | |||
| HUVECs | 53.1 nmol/L | Qiu et al. [130] | |||
| Het-1Aa | 10.1 μM | Lv et al. [133] | |||
| PBMCsb | 16.5 ± 4.7 ng/mL | Yuan et al. [144] | |||
| Primary normal human endometrial epithelial cells | Little sensitivity to BF from 0.1 to 10 ng/mL | Takai et al. [132] | |||
| PBMCs | 16.5 ± 4.7 ng/mL | Yuan et al. [144] |
aHuman normal esophageal squamous cells
bNormal peripheral blood mononuclear cells (PBMCs) were isolated from three healthy volunteers (32 ± 9 years of age)